Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy Aug 10, 2021 7:00am EDT
Trevena to Release Second Quarter 2021 Financial Results on August 12th, 2021 Aug 09, 2021 7:00am EDT
Trevena Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Trial of TRV027 for COVID-19 Jul 26, 2021 7:00am EDT
Trevena Announces Two Leading Independent Proxy Advisory Firms Recommend Shareholders Vote “For” All Proposals Ahead of Special Meeting of Stockholders Jul 23, 2021 7:00am EDT
Trevena Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research Jul 12, 2021 7:00am EDT
Trevena Announces First Patient Enrolled in OLINVYK® Phase 3 Trial in China in Partnership with Jiangsu Nhwa Pharmaceutical Jul 08, 2021 7:10am EDT
Trevena Announces Initiation of OLINVYK® Respiratory Physiology Study Including Elderly / Obese Subjects Jul 07, 2021 7:00am EDT
Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder Jun 16, 2021 7:00am EDT
